Exagen Inc. (XGN)
NASDAQ: XGN · Real-Time Price · USD
10.41
+0.08 (0.77%)
Nov 6, 2025, 11:14 AM EST - Market open
Exagen Revenue
Exagen had revenue of $17.24M in the quarter ending September 30, 2025, with 37.87% growth. This brings the company's revenue in the last twelve months to $63.60M, up 14.08% year-over-year. In the year 2024, Exagen had annual revenue of $55.64M with 5.89% growth.
Revenue (ttm)
$63.60M
Revenue Growth
+14.08%
P/S Ratio
3.29
Revenue / Employee
$295,809
Employees
215
Market Cap
229.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 55.64M | 3.09M | 5.89% |
| Dec 31, 2023 | 52.55M | 6.99M | 15.33% |
| Dec 31, 2022 | 45.56M | -2.74M | -5.66% |
| Dec 31, 2021 | 48.30M | 6.32M | 15.07% |
| Dec 31, 2020 | 41.98M | 1.59M | 3.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XGN News
- 1 day ago - Exagen Inc. (XGN) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Exagen Inc. Reports Strong Q3 2025 Results - GlobeNewsWire
- 14 days ago - Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence - GlobeNewsWire
- 15 days ago - Exagen Inc. to Announce Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 3 months ago - Exagen Inc. to Participate in Third Quarter Investor Conferences - GlobeNewsWire
- 3 months ago - Exagen Inc. (XGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Exagen Inc. Reports Strong Q2 2025 Results - GlobeNewsWire
- 3 months ago - Exagen Inc. Appoints Chas McKhann to Board of Directors - GlobeNewsWire